MFMichaela Feodoroff

Michaela Feodoroff

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michaela Feodoroff has a total of 112 co-authors. Here are the top co-authors by number of shared publications:

  • Vincenzo Cerullo

    Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland

    7 shared publications
  • Gabriella Antignani

    Drug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland

    5 shared publications
  • Mikaela Grönholm

    Drug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland

    5 shared publications
  • Salvatore Russo

    Drug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland

    5 shared publications
  • Vilja Pietiäinen

    Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland

    5 shared publications
  • Jacopo Chiaro

    Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland

    4 shared publications

Latest Publications

  • Open Access

    Site-Dependent Decoupling of Drug-Biomarker Associations in Clear Cell Renal Cell Carcinoma Revealed by Functional Profiling of Patient-Derived Cell Models

    by Michaela Feodoroff, Tamara J. Luck, Romika Kumari, Minttu Polso, Patrick Penttilä, Minna Malmstedt, Piia Mikkonen, Lauren J. Gerber, Ruusu Merivirta, Mariliina Arjama, et al.

    Clear cell renal cell carcinoma (ccRCC) frequently exhibits primary and acquired resistance to standard-of-care therapies, underscoring the need for improved strategies to predict therapeutic response and prioritize patient-specific treatments. Although recent multi-omic and single-cell studies have provided insight into the molecular landscape of ccRCC, molecular alterations alone incompletely predict drug sensitivity. We prospectively profiled tumors from 28 patients with localized and metastatic ccRCC by integrating molecular characterization, functional drug sensitivity and resistance testing in patient-derived cell models, and longitudinal clinical data. Although genomic biomarkers suggested potentially actionable therapies in 27/28 patients, functional testing revealed discordance between genomic actionability and ex vivo drug sensitivity, whereas linear mixed-effects modelling uncovered 16 novel copy-number-based features associated with sensitivity to 11 drugs. Genotype-drug response associations were largely preserved between primary tumors and vena cava thrombi but frequently disrupted in distant metastases. Integrating functional drug testing with multi-omic profiling reveals vulnerabilities not apparent from genomic data alone, refines therapeutic actionability, captures interpatient and intersite heterogeneity in ccRCC, and provides a scalable framework for individualized treatment prioritization.


  • Top Cited Papers
    Open Access

    Leveraging glucan-induced trained immunity for the epigenetic and metabolic rewiring of macrophages to enhance colorectal cancer vaccine response

    by Firas Hamdan, Sara Gandolfi, Federica D’aLessio, Yvonne Giannoula, Julia Kolikova, Manlio Fusciello, Elisa Zaghen, Alessandra Napolano, Salvatore Russo, Ozan Izci, et al.

    Colorectal cancer (CRC) remains refractory to most immunotherapies, with cancer vaccines failing due to an immunosuppressive tumor microenvironment. Here, we show that β-glucan–induced trained immunity overcomes these barriers by reprogramming macrophages through H3K4me3-dependent epigenetic modifications and metabolic rewiring. In female mice vaccinated with peptide-coated adenovirus-based vaccine PeptiCrad, training enhances glycolysis with creatine metabolism sustaining CXCL9/10 production, enabling macrophages to recruit NK cells via CXCR3. In turn, NK cells produce CCL5, driving cDC1 infiltration and antigen presentation, which together amplify effector memory CD8⁺ T cell responses. Moreover, with human peripheral blood mononuclear cells and CRC patient-derived organoids, trained macrophages boost NK migration, antigen-specific T cell activation, and tumor killing. These findings highlight trained immunity as a powerful adjuvant to reinvigorate colorectal cancer vaccination.


  • Open Access

    Functional screening identifies kinesin spindle protein inhibitor filanesib as a potential treatment option for hepatoblastoma

    by Ruth Nousiainen, Katja Eloranta, Jani Saarela, Antti Hassinen, Tamara J. Luck, Stefano Cairo, Emilie Indersie, Swapnil Potdar, Michaela J. Feodoroff, Jouko Lohi, et al.

    Hepatoblastoma is a rare pediatric liver malignancy usually treated with surgery and chemotherapy. To explore new treatment options for hepatoblastoma, drug screening was performed using six cell models established from aggressive hepatoblastoma tumors and healthy pediatric primary hepatocytes. Of the 527 screened compounds, 98 demonstrated cancer-selective activity in at least one hepatoblastoma model. The kinesin spindle protein (KSP) inhibitor filanesib was effective in all models and was further evaluated. Filanesib induced G2/M arrest and apoptosis in hepatoblastoma cells at concentrations tolerable to primary hepatocytes. Prominent nuclear fragmentation was observed in filanesib-treated hepatoblastoma cells. Genes participating in cell cycle regulation were noted to be differentially expressed after filanesib treatment. Filanesib reduced the rate of tumor growth in 4/5 hepatoblastoma mice models. One of these models showed complete growth arrest. Our results suggest that filanesib is a potential candidate for hepatoblastoma treatment and should be investigated in future clinical trials.


  • Open Access

    Achieving high-resolution single-cell segmentation in convoluted cancer spheroids via Bayesian optimization and deep-learning

    by Isabel Mogollon, Michaela Feodoroff, Anna Nylund, Alba Montedeoca, Gantugs Atarsaikhan, Pedro Neto, Peter Horvath, Antti Rannikko, Vincenzo Cerullo, Vilja Pietiäinen, et al.

    Understanding cellular function within 3D multicellular spheroids is essential for advancing cancer research, particularly in studying cell-stromal interactions as potential targets for novel drug therapies. However, accurate single-cell segmentation in 3D cultures is challenging due to dense cell clustering and the impracticality of manual annotations. We present a high-throughput (HT) 3D single-cell analysis pipeline that combines optimized wet-lab conditions, deep learning (DL)-based segmentation models, and Bayesian optimization to address these challenges. By using live-cell nuclear and cytoplasmic dyes, we achieved clear and uniform staining of cell populations in renal cancer and immune T-cell monocultures and cocultures, improving single-cell detection in spheroids. Our pipeline integrates image preprocessing and DL models based on 3DUnet architecture, enabling robust segmentation of densely packed 3D structures. Bayesian optimization, guided by a custom objective function, was employed to refine segmentation parameters and improve quality based on biologically relevant criteria. The pipeline successfully segments cells under various drug treatments, revealing drug-induced changes not detectable by bulk conventional assays. This approach has potential for application to more complex biological samples, including, organoid co-cultures, diverse drug treatments, and integration with additional immunostaining assays, paving the way for detailed HT analyses of single-cell responses.


  • Open Access

    Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome

    by Mariia S. Bogacheva, Suvi Kuivanen, Swapnil Potdar, Antti Hassinen, Sini Huuskonen, Ina Pöhner, Tamara J. Luck, Laura Turunen, Michaela Feodoroff, Leonora Szirovicza, et al.


  • Open Access

    Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors

    by Jacopo Chiaro, Gabriella Antignani, Sara Feola, Michaela Feodoroff, Beatriz Martins, Hanne Cojoc, Salvatore Russo, Manlio Fusciello, Firas Hamdan, Valentina Ferrari, et al.

    Malignant pleural mesothelioma (MPM) is an aggressive tumor with a poor prognosis. As the available therapeutic options show a lack of efficacy, novel therapeutic strategies are urgently needed. Given its T-cell infiltration, we hypothesized that MPM is a suitable target for therapeutic cancer vaccination. To date, research on mesothelioma has focused on the identification of molecular signatures to better classify and characterize the disease, and little is known about therapeutic targets that engage cytotoxic (CD8+) T cells. In this study we investigate the immunopeptidomic antigen-presented landscape of MPM in both murine (AB12 cell line) and human cell lines (H28, MSTO-211H, H2452, and JL1), as well as in patients’ primary tumors. Applying state-of-the-art immuno-affinity purification methodologies, we identify MHC I-restricted peptides presented on the surface of malignant cells. We characterize in vitro the immunogenicity profile of the eluted peptides using T cells from human healthy donors and cancer patients. Furthermore, we use the most promising peptides to formulate an oncolytic virus-based precision immunotherapy (PeptiCRAd) and test its efficacy in a mouse model of mesothelioma in female mice. Overall, we demonstrate that the use of immunopeptidomic analysis in combination with oncolytic immunotherapy represents a feasible and effective strategy to tackle untreatable tumors.


  • Open Access

    Comparison of two supporting matrices for patient-derived cancer cells in 3D drug sensitivity and resistance testing assay (3D-DSRT)

    by Michaela Feodoroff, Piia Mikkonen, Laura Turunen, Antti Hassinen, Lauri Paasonen, Lassi Paavolainen, Swapnil Potdar, Astrid Murumägi, Olli Kallioniemi, Vilja Pietiäinen


  • Open Access

    Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses

    by Firas Hamdan, Michaela Feodoroff, Salvatore Russo, Manlio Fusciello, Sara Feola, Jacopo Chiaro, Gabriella Antignani, Francesca Greco, Jeanette Leusen, Erkko Ylösmäki, et al.


  • Open Access

    Protocol for 3D drug sensitivity and resistance testing of patient-derived cancer cells in 384-well plates

    by Michaela Feodoroff, Piia Mikkonen, Mariliina Arjama, Astrid Murumägi, Olli Kallioniemi, Swapnil Potdar, Laura Turunen, Vilja Pietiäinen


  • Open Access

    Development of mesothelioma-specific oncolytic vaccine exploiting immunopeptidomic analysis of murine and human tumors

    by Jacopo Chiaro, Gabriella Antignani, Sara Feola, Michaela Feodoroff, Beatriz Martins, Hanne Cojoc, Valentina Ferrari, Daniele Ciampi, Ilkka Ilonen, Jari Räsänen, et al.

    Malignant pleural mesothelioma (MPM) is an aggressive tumor with a poor prognosis. As the available therapeutic options show a lack of efficacy, novel treatments and therapeutic targets are urgently needed. It has been observed that MPM is responsive to immunotherapeutic cancer treatments, and given its T-cell infiltration, we hypothesized that MPM is a suitable target for therapeutic cancer vaccination. To date, research on mesothelioma has focused on the identification of molecular signatures to better classify and characterize the disease, and little is known about therapeutic targets to engage cytotoxic (CD8+) T cells. In this study, for the first time, we explored the immunopeptidomic antigen-presented landscape of MPM in both murine (AB12 cell line), human cell lines (H28, MSTO-211H, H2452, and JL1), and in patients' primary tumors. Applying state-of-art MHC immuno-affinity purification methodologies, we identified MHC-I-restricted peptides presented on the surface of malignant cells. We characterized some newly discovered patients-derived peptides utilizing in vitro co-culturing techniques, demonstrating that eluted peptides showed promising immunogenicity profiles. Additionally, we provided a proof-of-concept for the application of a whole antigen discovery pipeline using immunopeptidomics for cancer vaccine development in a murine model of MPM. Overall, we investigated the antigen landscape of MPM and showed that the discovered peptides show potential to be used for therapeutic cancer vaccine.